KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arbutus Biopharma (ABUS) Change in Accured Expenses (2016 - 2025)

Arbutus Biopharma's Change in Accured Expenses history spans 13 years, with the latest figure at $2.7 million for Q3 2025.

  • For Q3 2025, Change in Accured Expenses rose 334.12% year-over-year to $2.7 million; the TTM value through Sep 2025 reached -$2.8 million, down 503.25%, while the annual FY2024 figure was -$2.7 million, 509.68% down from the prior year.
  • Change in Accured Expenses for Q3 2025 was $2.7 million at Arbutus Biopharma, up from -$3.0 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $6.9 million in Q3 2023 and bottomed at -$6.4 million in Q1 2023.
  • The 5-year median for Change in Accured Expenses is -$104000.0 (2025), against an average of $189263.2.
  • The largest annual shift saw Change in Accured Expenses soared 86850.0% in 2022 before it plummeted 8401.33% in 2023.
  • A 5-year view of Change in Accured Expenses shows it stood at $2.2 million in 2021, then skyrocketed by 74.56% to $3.8 million in 2022, then plummeted by 104.12% to -$155000.0 in 2023, then crashed by 1449.03% to -$2.4 million in 2024, then soared by 211.45% to $2.7 million in 2025.
  • Per Business Quant, the three most recent readings for ABUS's Change in Accured Expenses are $2.7 million (Q3 2025), -$3.0 million (Q2 2025), and -$104000.0 (Q1 2025).